Molecular Basis of Chemosensitivity of Platinum Pre-Treated Ovarian Cancer to Chemotherapy

British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6605817
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Chemotherapy-Free Strategy for Platinum-Sensitive Recurrent Ovarian Cancer

The Lancet Oncology
Oncology
2019English

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab

Clinical Medicine Insights: Oncology
Oncology
2019English

Preference of Elderly Patients’ to Oral or Intravenous Chemotherapy in Heavily Pre-Treated Recurrent Ovarian Cancer: Final Results of a Prospective Multicenter Trial

Gynecologic Oncology Research and Practice
2017English

Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study

Asian Pacific Journal of Cancer Prevention
2019English

Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched With Patients Treated With Parenteral Chemotherapy

Anticancer Research
MedicineCancer ResearchOncology
2016English

Epoetin Alfa in Platinum-Treated Ovarian Cancer Patients: Results of a Multinational, Multicentre, Randomised Trial

British Journal of Cancer
Cancer ResearchOncology
2006English

Molecular Basis of Ovarian Development and Function

Frontiers in Bioscience - Landmark
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2002English

Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Knockdown of Cathepsin�L Sensitizes Ovarian Cancer Cells to Chemotherapy

Oncology Letters
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy